ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

SEER Program Expansion Through Cost-Sharing.

March 23, 2001

Cancer Control Budget Still $4 Million Short

January 28, 1977

RFP: Sole Source

May 12, 2000

Braun Named Executive Director Of ASCO Foundation

November 17, 2006

Statins Associated With Lower Risk Of High-Grade Prostate Cancer

March 25, 2011

Micafungin Bests Fluconazole In Phase III Antifungal Trial

November 29, 2002